Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.37 |
| ▸ | NQO2 | P16083 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 3/20 | 0.36 |
| ▸ | RAB9A | P51151 | 3/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.36 |
| ▸ | CASP3 | P42574 | 1/20 | 0.36 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.36 |
| ▸ | ALKBH5 | Q6P6C2 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | RAD52 | P43351 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL697978 | 0.83 | HSP90AA1 (0.39) | KMT2AALDH1A1MAPTMEN1CYP19A1 | |
| SCHEMBL8336073 | 0.80 | SLC6A3 (0.36) | KMT2AMAPTMEN1NPC1RAB9A | |
| SCHEMBL27899 | 0.80 | ABCG2 (0.39) | PKMCYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL2076685 | 0.80 | ABCG2 (0.39) | PKMCYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL29352284 | 0.80 | ABCG2 (0.39) | PKMCYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL5708460 | 0.79 | TRPV1 (0.33) | ALDH1A1MAPTKDM4ESMN1; SMN2HPGD | |
| SCHEMBL5896988 | 0.79 | NQO2 (0.38) | KMT2AMEN1CYP19A1NQO2KDM4E | |
| SCHEMBL6904608 | 0.78 | ABCG2 (0.38) | PKMCYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL698217 | 0.77 | NQO2 (0.37) | KMT2AALDH1A1MAPTMEN1CYP19A1 | |
| SCHEMBL29565955 | 0.77 | NQO2 (0.37) | KMT2AALDH1A1MAPTMEN1CYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1650207-B1 | Process for producing optically active 3-quinuclidinols | TAKASAGO PERFUMERY CO LTD (JP) | 2007-06-27 | — | — | EP | claimed |
| US-20220169600-A1 | METHOD FOR PRODUCING PKROSTAGLANDIN | KYOWA PHARMA CHEMICAL CO., LTD. (JP) | 2022-06-02 | — | — | US | disclosed |
| EP-3199513-B1 | PROCESS FOR PRODUCING ALCOHOL ANALOGUE | TAKASAGO PERFUMERY CO LTD (JP) | 2019-05-08 | — | — | EP | disclosed |
| US-10029968-B2 | Process for producing alcohol analogue | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2018-07-24 | — | — | US | disclosed |
| US-20170297990-A1 | PROCESS FOR PRODUCING ALCOHOL ANALOGUE | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2017-10-19 | — | — | US | disclosed |
| EP-3199513-A1 | PROCESS FOR PRODUCING ALCOHOL ANALOGUE | Takasago International Corporation (JP) | 2017-08-02 | — | — | EP | disclosed |
| EP-2774908-B1 | METHOD FOR PREVENTING DECREASE IN OPTICAL PURITY | TAKASAGO PERFUMERY CO LTD (JP) | 2017-02-08 | — | — | EP | disclosed |
| US-9328079-B2 | Process for producing optically active amine | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2016-05-03 | — | — | US | disclosed |
| US-9255049-B2 | Ruthenium complex and method for preparing optically active alcohol compounds using the same as a catalyst | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2016-02-09 | — | — | US | disclosed |
| EP-2611819-B1 | IRIDIUM COMPLEX AND METHOD FOR PRODUCING OPTICALLY ACTIVE COMPOUND | TAKASAGO PERFUMERY CO LTD (JP) | 2015-12-16 | — | — | EP | disclosed |
| EP-2060578-A1 | PROCESS FOR PRODUCTION OF OPTICALLY ACTIVE AMINOPHOSPHINYLBUTANOIC ACID | MEIJI SEIKA KAISHA LTD. (JP) | 2009-05-20 | — | — | EP | disclosed |
| US-20090036696-A1 | IRIDIUM COMPLEXES | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2009-02-05 | — | — | US | disclosed |
| US-7462722-B2 | Process for producing optically active-3-quinuclidinols | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2008-12-09 | — | — | US | disclosed |
| EP-1935896-A1 | Novel optically active biaryl phosphorus compound and production process thereof | National University Corporation Tokyo University of Agriculture and Technology (JP) | 2008-06-25 | — | — | EP | disclosed |
| US-20080139822-A1 | Novel optically active biaryl phosphorus compound and production process thereof | MAXWELL TECHNOLOGIES, INC. | 2008-06-12 | — | — | US | disclosed |
| EP-1650207-B1 | Process for producing optically active 3-quinuclidinols | TAKASAGO PERFUMERY CO LTD (JP) | 2007-06-27 | — | — | EP | disclosed |
| US-20060199973-A1 | Process for producing an alcohol or a silyl ether thereof | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2006-09-07 | — | — | US | disclosed |
| EP-1650207-A1 | Process for producing optically active 3-quinuclidinols | Takasago International Corporation (JP) | 2006-04-26 | — | — | EP | disclosed |
| US-20060047122-A1 | Process for producing optically active-3-quinuclidinols | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2006-03-02 | — | — | US | disclosed |
| US-5872273-A | LIGANDS FOR FORMING HYDROGENATION CATALYST COMPLEXES | TAKASAGO INTERNATIONAL CORPORATION (JP) | 1999-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090036696-A1 | IRIDIUM COMPLEXES | HAX1, MLX, H1-0 | KMT2A 2830/4885ALDH1A1 1340/4885MAPT 4800/4885 |
| US-20060199973-A1 | Process for producing an alcohol or a silyl ether thereof | CBR1, RER1, ADH1A | KMT2A 765/4885ALDH1A1 534/4885MAPT 3546/4885 |
| US-20220169600-A1 | METHOD FOR PRODUCING PKROSTAGLANDIN | PTGS1, PTGER1, RACK1 | KMT2A 2066/4885ALDH1A1 1425/4885MAPT 4859/4885 |
| US-20060047122-A1 | Process for producing optically active-3-quinuclidinols | DHPS, QDPR, TYR | KMT2A 1075/4885ALDH1A1 1219/4885MAPT 1962/4885 |
| US-20080139822-A1 | Novel optically active biaryl phosphorus compound and production process thereof | PHOSPHO1, DHRS9, HDHD5 | KMT2A 2489/4885ALDH1A1 2036/4885MAPT 4875/4885 |
| US-20170297990-A1 | PROCESS FOR PRODUCING ALCOHOL ANALOGUE | ADH1A, ADH1C, ADH5 | KMT2A 1658/4885ALDH1A1 11/4885MAPT 2582/4885 |
| US-10029968-B2 | Process for producing alcohol analogue | ADH1A, ADH1C, ADH5 | KMT2A 1658/4885ALDH1A1 11/4885MAPT 2582/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.